Novel Induction to Buprenorphine/Naloxone

Launched by BICYCLE HEALTH · Nov 30, 2022

Keywords

ClinConnect Summary

Medication for OUD (MOUD) is a first-line treatment for OUD and improves outcomes in mortality, retention in treatment, and non-prescribed opioid use. Buprenorphine/naloxone is the only MOUD of the three FDA-approved medications for OUD available in the telehealth setting, as methadone and injectable naltrexone must be managed in an in-person setting. Buprenorphine/naloxone, also referred to as brand name Suboxone, is administered by placing a film strip under the tongue. Buprenorphine acts as a partial agonist with a high binding affinity at the mu-opioid receptor; clearance of the pure op...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Enrollment with Bicycle Health services
• • Aged 18 years old or older
• • Diagnosis of opioid use disorder confirmed by DSM-5 criteria
• • In no/mild withdrawal at the time of intake
• • Need to undergo induction to buprenorphine from a full opioid agonist
• • Use of full opioid agonists not directly from a pharmacy within the last 24 hours
• • Pharmacy stock check of 2 mg film/tablet done before visit
• • Willingness and ability to follow study protocols, and the ability to provide informed consent
• Exclusion Criteria:
• • Known allergy or sensitivity to buprenorphine/naloxone
• • Any circumstance that precludes the need for induction
• • In moderate to severe withdrawal at the time of intake
• • Severe or complex medical/psychiatric comorbidity that requires a customized induction schedule or surveillance
• • Any element that would exclude an individual from Bicycle Health services in general (e.g., homelessness, severe untreated mental illness)
• • Patients requesting specific induction technique
• • Patients who are pregnant or lactating

Trial Officials